Japan

BMI Core View: Personalised medicines will play a greater role in the treatment of patients. They offer fewer side-effects and treat illnesses more efficiently than wide-spectrum therapeutics.... 2010-07-28

BMI Core View: Offshoring manufacturing to low cost bases will accelerate. Multinational drugmakers are looking to cut costs ahead of the patent cliff and production is being shifted... 2010-07-26

Multinational drugmaker Sanofi-Aventis is to invest JPY5bn (US$55mn) to obtain a 5% stake in Japanese drugmaker Nichi-Iko, making it the second largest shareholder in the company, after... 2010-05-27

Japan-based Panasonic has announced expansion plans for its Singapore research and development (R&D) centre, which currently focuses on the audiovisual, automotive, computer and... 2010-04-26

Fujitsu is the latest example of a non-healthcare company entering the medical services sector, thereby endorsing one of BMI's core views for the pharmaceuticals and healthcare industry.... 2010-04-20

Eisai is to cut the price of its Alzheimer's disease therapeutic Aricept (donepezil) in six Asian countries. BMI notes that this tactic is in accordance with one of our short-term... 2010-04-16

It is BMI's view that adhering to quality manufacturing standards is one of the few fundamental responsibilities of a pharmaceutical company. Synthesis of active pharmaceutical ingredients... 2010-04-15

Japan is no longer the most attractive pharmaceutical market in Asia Pacific, according to BMI's Q310 Pharmaceuticals & Healthcare Business Environment Ratings (BERs) for the region.... 2010-04-13

Multinational drugmaker GlaxoSmithKline (GSK) is looking to invest in small- and medium-sized pharmaceutical and biotechnology companies in Japan, reinforcing the company's strategic... 2010-03-29

BMI's newest long-term core view is that the generic drug industry will stratify into the following sub-sectors: unbranded/commodity generics; branded generics; value-added generics;... 2010-03-29